Skip to main content

Table 2 Base case clinical results: fractures avoided per 1,000 patients

From: The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden

Cohort Evaluated Hip Fractures Vertebral Fractures Wrist Fractures
PMO Patients (100% Female), age 69 years, T-Score = −3.0
historical vertebral + incident vertebral fracture    
 Teriparatide vs. No Treatment 95 221 32
 Teriparatide vs. bisphosphonate 66 166 27
incident vertebral fracture    
 Teriparatide vs. No Treatment 73 145 27
 Teriparatide vs. bisphosphonate 51 108 22
GIOP Patients (80% Female), age 69 years, T-Score = −2.5
historical vertebral + incident vertebral fracture    
 Teriparatide vs. No Treatment 93 304 36
 Teriparatide vs. bisphosphonate 63 227 30
incident vertebral fracture    
 Teriparatide vs. No Treatment 85 248 34
 Teriparatide vs. bisphosphonate 57 184 28